Pulmonology Xagena
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Relvar Ellipta ( Fluticason ...
Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting beta-2 agonist is more protective than a once-daily longacting beta-2 agonist alone against exacerbations of ...
Fluticasone furoate / Vilanterol ( FF/VI; Relvar Ellipta ) is an inhaled corticosteroid / long-acting beta2-agonist ( ICS / LABA ), recently approved as once-daily maintenance therapy for COPD. Rese ...
Results from two phase III studies were presented. They have shown that patients with chronic obstructive pulmonary disease ( COPD ) who received the anticholinergic, Incruse Ellipta ( Umeclidinium 62 ...
Increased arterial stiffness as measured by aortic pulse wave velocity ( aPWV ) predicts cardiovascular events and mortality and is elevated in patients with COPD ( chronic obstructive pulmonary disea ...
